초기 삼중음성 유방암에서 신보조요법으로서 니볼루맙 단독 또는 니볼루맙과 이필리무맙 병용: 2상 적응형 임상시험

Nederlof 등(월요일)은 이 질문에 대해 연구했습니다.

www.synapsesocial.com/papers/68e58475b6db643587521371 — DOI: https://doi.org/10.1038/s41591-024-03249-3

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. RSeQC: quality control of RNA-seq experiments· 2012 · 2,985 citations
2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,244 citations
3. Tertiary lymphoid structures improve immunotherapy and survival in melanoma· 2020 · 2,308 citations
4. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer· 2023 · 18 citations
5. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial· 2024 · 105 citations